MapLight Therapeutics, Inc.(MPLT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MPLT MapLight Therapeutics, Inc.

Pre-Mkt 06-02 07:02:44 EDT

29.76

+0.45

+1.54%

High30.03	Low28.40	Vol270.55K
Open28.99	D1 Closing29.31	Amplitude5.56%
Mkt Cap1.35B	Tradable Cap326.67M	Total Shares45.35M
T/O7.99M	T/O Rate2.46%	Tradable Shares10.98M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MPLT","market":"US","secType":"STK","nameCN":"MapLight Therapeutics, Inc.","latestPrice":29.76,"timestamp":1780344000000,"preClose":29.31,"halted":0,"volume":270553,"delay":0,"changeRate":0.015353121801433056,"floatShares":10976700,"shares":45345700,"eps":-4.412,"marketStatus":"Pre-Mkt","change":0.45,"latestTime":"06-02 07:02:44 EDT","open":28.99,"high":30.03,"low":28.4,"amount":7988666,"amplitude":0.055612,"askPrice":32,"askSize":110,"bidPrice":24.5,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-4.412,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1780407000000},"marketStatusCode":1,"adr":0,"listingDate":1761537600000,"exchange":"NASDAQ","adjPreClose":29.76,"postHourTrading":{"tag":"盘后","latestPrice":30,"preClose":29.76,"latestTime":"16:10 EDT","volume":27078,"amount":811841.28,"timestamp":1780344605369,"change":0.24,"changeRate":0.008065,"amplitude":0},"volumeRatio":0.8626772127285591,"impliedVol":1.9967,"impliedVolPercentile":0.5},"requestUrl":"/m/hq/s/MPLT/wiki","defaultTab":"wiki","newsList":[{"id":"2640914702","title":"Maplight Therapeutics Inc : Stifel Raises Target Price to $36 From $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2640914702","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640914702?lang=en_us&edition=fundamental","pubTime":"2026-06-02 18:32","pubTimestamp":1780396344,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nFWN42A0HC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640384933","title":"Assessing MapLight Therapeutics (MPLT) Valuation After Strong Recent Share Price Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2640384933","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640384933?lang=en_us&edition=fundamental","pubTime":"2026-06-01 12:30","pubTimestamp":1780288234,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics stock reaction\nMapLight Therapeutics (MPLT) has drawn investor attention after recent trading, with the stock at $29.31 and showing sharp moves over the past 3 months alongside mixed short term returns.\nSee our latest analysis for MapLight Therapeutics.\nFor context, the 1-day share price return declined 1.58%, while the 90-day share price return of 66.53% and year to date share price return of 74.78% point to strong recent momentum despite a softer 30-day share price...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mplt/maplight-therapeutics/news/assessing-maplight-therapeutics-mplt-valuation-after-strong","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mplt/maplight-therapeutics/news/assessing-maplight-therapeutics-mplt-valuation-after-strong","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638693745","title":"MapLight Therapeutics Price Target Maintained With a $45.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2638693745","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638693745?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:34","pubTimestamp":1779971640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MPLT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 28, 2026 08:34 ET (12:34 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638768079","title":"MapLight Therapeutics Initiated at Buy by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2638768079","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638768079?lang=en_us&edition=fundamental","pubTime":"2026-05-28 02:17","pubTimestamp":1779905820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MPLT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 27, 2026 14:17 ET (18:17 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638181528","title":"MapLight Therapeutics initiated with a Buy at UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2638181528","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638181528?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:27","pubTimestamp":1779827247,"startTime":"0","endTime":"0","summary":"UBS analyst Ashwani Verma initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and $48 price target MapLight has a “major near-term...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-initiated-with-a-buy-at-ubs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-initiated-with-a-buy-at-ubs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4118","BK4534","BK4588","BK4139","UBS","BK4585","LU1829250122.USD","LU3187612489.SGD","LU1863844749.USD","MPLT","IE0034235071.USD","LU1863844665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195658206","title":"Stock Track | MapLight Therapeutics Soars 5.11% Intraday on Craig-Hallum Buy Initiation with $43 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1195658206","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195658206?lang=en_us&edition=fundamental","pubTime":"2026-05-22 04:00","pubTimestamp":1779393630,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics, Inc. (MPLT) saw its stock price soar 5.11% during intraday trading on Thursday, marking a significant upward movement for the biopharmaceutical company.The surge appears to be...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637355098","title":"MapLight Therapeutics Initiated at Buy by Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2637355098","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637355098?lang=en_us&edition=fundamental","pubTime":"2026-05-22 02:00","pubTimestamp":1779386400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MPLT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 21, 2026 14:00 ET (18:00 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637339532","title":"Craig-Hallum bullish on MapLight Therapeutics, initiates with a Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2637339532","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637339532?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:50","pubTimestamp":1779367809,"startTime":"0","endTime":"0","summary":"As previously reported, Craig-Hallum initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and $43 price target The firm views MapLi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/craig-hallum-bullish-on-maplight-therapeutics-initiates-with-a-buy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/craig-hallum-bullish-on-maplight-therapeutics-initiates-with-a-buy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636084336","title":"Analyst Reiterates Buy on MapLight, Maintains $37 Price Target on Confidence in ML-007 and Pipeline Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2636084336","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636084336?lang=en_us&edition=fundamental","pubTime":"2026-05-20 17:45","pubTimestamp":1779270331,"startTime":"0","endTime":"0","summary":"In a report released today, Ami Fadia from Needham maintained a Buy rating on MapLight Therapeutics, Inc., with a price target of $37.00. Ami Fadia...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-maplight-maintains-37-price-target-on-confidence-in-ml-007-and-pipeline-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-maplight-maintains-37-price-target-on-confidence-in-ml-007-and-pipeline-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636831708","title":"Maplight CEO Christopher Kroeger sells $3.21 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2636831708","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636831708?lang=en_us&edition=fundamental","pubTime":"2026-05-19 09:27","pubTimestamp":1779154067,"startTime":"0","endTime":"0","summary":"Maplight Therapeutics CEO Christopher A. Kroeger sold 118,235 shares of voting common stock on May 18, 2026 at weighted average prices of USD 27.19 and USD 28.15.His direct holdings fell to 1,394,094 shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDLLyXRG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maplight CEO Christopher Kroeger sells $3.21 million common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635814910","title":"Buy Rating Reiterated on Clinical Catalysts and Strong Cash Runway; $37 Price Target Unchanged","url":"https://stock-news.laohu8.com/highlight/detail?id=2635814910","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635814910?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:55","pubTimestamp":1778846138,"startTime":"0","endTime":"0","summary":"Analyst Ami Fadia from Needham maintained a Buy rating on MapLight Therapeutics, Inc. and keeping the price target at $37.00. Ami Fadia has given h...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-reiterated-on-clinical-catalysts-and-strong-cash-runway-37-price-target-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-reiterated-on-clinical-catalysts-and-strong-cash-runway-37-price-target-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635724241","title":"MapLight Therapeutics Expands Pipeline Amid Rising Quarterly Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2635724241","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635724241?lang=en_us&edition=fundamental","pubTime":"2026-05-15 06:26","pubTimestamp":1778797584,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics, Inc. ( ($MPLT) ) has shared an update. MapLight Therapeutics reported first-quarter 2026 results on May 14, highlighting an ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maplight-therapeutics-expands-pipeline-amid-rising-quarterly-losses?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maplight-therapeutics-expands-pipeline-amid-rising-quarterly-losses?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635562729","title":"MapLight Therapeutics reports Q1 EPS ($1.34), consensus ($1.12)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635562729","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635562729?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:45","pubTimestamp":1778791503,"startTime":"0","endTime":"0","summary":"“We are continuing to see strong momentum across our clinical portfolio, including completion of enrollment in the Phase 2 ZEPHYR and IRIS trials,”...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-reports-q1-eps-1-34-consensus-1-12-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-reports-q1-eps-1-34-consensus-1-12-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635272642","title":"MapLight Therapeutics Q1 EPS $(1.34) Misses $(1.11) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635272642","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635272642?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:44","pubTimestamp":1778791445,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(1.34) per share which missed the analyst consensus estimate of $(1.11) by 20.72 percent. This is a 95.43 percent increase over losses of $(29.33) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52582713/maplight-therapeutics-q1-eps-1-34-misses-1-11-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"MapLight Therapeutics Q1 EPS $(1.34) Misses $(1.11) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635725291","title":"Maplight Therapeutics Q1 FY26 net loss widens to $60.67 million from year-ago quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2635725291","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635725291?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:27","pubTimestamp":1778790437,"startTime":"0","endTime":"0","summary":"Maplight Therapeutics posted a net loss of USD 60.67 million for the quarter ended March 31, 2026, widening from USD 22.34 million a year earlier.Operating loss widened to USD 64.5 million as operating expenses more than doubled to USD 64.5 million.Research and development expense climbed to USD 53.68 million, driven by higher clinical trial costs of USD 24.82 million and employee-related expense of USD 15.99 million.General and administrative expense rose to USD 10.82 million on higher employee-related costs of USD 6.99 million.Cash, cash equivalents and investments totaled USD 395.2 million at March 31, 2026; ZEPHYR Phase 2 schizophrenia trial completed enrollment with 307 participants, with topline results expected by mid-August 2026, while IRIS Phase 2 ASD trial topline data are also expected by mid-August 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL2rQGJm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635264297","title":"Maplight Therapeutics Inc:  Q1 EPS $-1.34","url":"https://stock-news.laohu8.com/highlight/detail?id=2635264297","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635264297?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:05","pubTimestamp":1778789107,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUABNZNJ5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635723955","title":"Press Release: MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635723955","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635723955?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:05","pubTimestamp":1778789100,"startTime":"0","endTime":"0","summary":"-- Enrollment completed in ML-007C-MA's Phase 2 ZEPHYR trial in. schizophrenia, with topline results expected by mid-August 2026. -- Last patient visit completed for ML-004's Phase 2 IRIS trial in autism. -- Enrollment ongoing in ML-007C-MA's Phase 2 VISTA trial in Alzheimer's. disease psychosis, with topline results expected in the second half of. -- Ended the quarter with $395.2 million in cash, cash equivalents and. investments, which is expected to fund operations through 2027. \"We are continuing to see strong momentum across our clinical portfolio, including completion of enrollment in the Phase 2 ZEPHYR and IRIS trials, \" said Chris Kroeger, co-Founder and Chief Executive Officer of the Company. \"With topline results from both studies expected by mid-August, continued advancement of our VISTA trial in Alzheimer's disease psychosis and progress across our early-stage pipeline, MapLight is entering an important inflection point in our mission to improve the lives of patients living","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0494093205.USD","IE00BFSS7M15.SGD","IE000MB6IJN5.SGD","LU0957791311.USD","ADP","IE00B775H168.HKD","LU2506951958.HKD","LU2552382132.HKD","BK4106","LU1868837136.USD","LU2361044865.SGD","IE00B4JS1V06.HKD","LU2756315664.SGD","LU2168564149.EUR","LU1037948897.HKD","LU1712237335.SGD","LU0965509101.SGD","LU2404859741.USD","MA","LU0198837287.USD","LU1236620750.USD","ABI","IE000WAW04H5.SGD","LU2023250330.USD","LU0823421416.USD","LU0690374615.EUR","BK4227","MPLT","LU0094547139.USD","LU1718418525.SGD","LU2896262040.SGD","IE000SO60NU8.SGD","LU0170899867.USD","LU0868494617.USD","LU1363072403.SGD","LU1989772840.SGD","LU0965509283.SGD","LU0234572021.USD","BK4566","LU0390134368.USD","LU1803068979.SGD","LU1236620834.HKD","IE00B1XK9C88.USD","SG9999000418.SGD","LU0950375773.USD","LU0820561818.USD","LU0061474705.USD","LU0061474960.USD","LU1228905540.USD","SGXZ81514606.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635240982","title":"MapLight Therapeutics management to meet with Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2635240982","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635240982?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:10","pubTimestamp":1778616657,"startTime":"0","endTime":"0","summary":"Meeting to be held on May 19 in New York hosted by Needham. Published first on TheFly – the ultimate source for real-time, market-moving breaking f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-management-to-meet-with-needham-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-management-to-meet-with-needham-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634252607","title":"Maplight CMO Erin Pennock Foff sells USD 126,664 common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2634252607","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634252607?lang=en_us&edition=fundamental","pubTime":"2026-05-12 09:30","pubTimestamp":1778549449,"startTime":"0","endTime":"0","summary":"Maplight Therapeutics Chief Medical Officer Erin Pennock Foff sold 4,438 shares of voting common stock on May 7, 2026.Sales were executed at weighted average prices of USD 28.52 and USD 29.1.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL1Z5Hwg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634252605","title":"Maplight Therapeutics General Counsel Kristopher Hanson sells shares worth $421,760.64","url":"https://stock-news.laohu8.com/highlight/detail?id=2634252605","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634252605?lang=en_us&edition=fundamental","pubTime":"2026-05-12 09:30","pubTimestamp":1778549448,"startTime":"0","endTime":"0","summary":"Maplight Therapeutics General Counsel Kristopher L. Hanson reported sales of 13,917 shares of voting common stock on May 11, 2026.Sales were reported at weighted average prices ranging from $27.61 to $30.56.Hanson’s direct holding fell to 162,331 shares following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL81V4dw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maplight Therapeutics General Counsel Kristopher Hanson sells shares worth $421,760.64","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.maplightrx.com","stockEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":-0.0306},{"period":"3month","weight":0.6524},{"period":"6month","weight":0.7589},{"period":"1year","weight":0.7506},{"period":"ytd","weight":0.6943}],"compareEarnings":[{"period":"1week","weight":0.0173},{"period":"1month","weight":0.0526},{"period":"3month","weight":0.115},{"period":"6month","weight":0.1092},{"period":"1year","weight":0.287},{"period":"ytd","weight":0.1124}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"MapLight Therapeutics, Inc.","nameEN":"MapLight Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MapLight Therapeutics, Inc.(MPLT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MapLight Therapeutics, Inc.(MPLT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MapLight Therapeutics, Inc.,MPLT,MapLight Therapeutics, Inc.股票,MapLight Therapeutics, Inc.股票老虎,MapLight Therapeutics, Inc.股票老虎国际,MapLight Therapeutics, Inc.行情,MapLight Therapeutics, Inc.股票行情,MapLight Therapeutics, Inc.股价,MapLight Therapeutics, Inc.股市,MapLight Therapeutics, Inc.股票价格,MapLight Therapeutics, Inc.股票交易,MapLight Therapeutics, Inc.股票购买,MapLight Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MapLight Therapeutics, Inc.(MPLT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MapLight Therapeutics, Inc.(MPLT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}